Araujo-Castro, MartaGarcía Centeno, RogelioRobles Lázaro, CristinaParra Ramírez, PaolaGracia Gimeno, PaolaRojas-Marcos, Patricia MartínFernández-Ladreda, Mariana ToméPercovich Hualpa, Juan CarlosSampedro Núñez, MiguelLópez-García, María-CarmenLamas, CristinaÁlvarez Escolá, CristinaCalatayud Gutiérrez, MaríaBlanco Carrera, Concepciónde Miguel Novoa, PazValdés Gallego, NuriaHanzu, FeliciaMarazuela, MónicaMora Porta, MireiaMínguez Ojeda, CésarGarcía Gómez Muriel, IsabelEscobar-Morreale, Héctor FValderrabano, Pablo2023-05-032023-05-032022-02-17http://hdl.handle.net/10668/19589The purpose of our study was to develop a predictive model to rule out pheochromocytoma among adrenal tumours, based on unenhanced computed tomography (CT) and/or magnetic resonance imaging (MRI) features. We performed a retrospective multicentre study of 1131 patients presenting with adrenal lesions including 163 subjects with histological confirmation of pheochromocytoma (PHEO), and 968 patients showing no clinical suspicion of pheochromocytoma in whom plasma and/or urinary metanephrines and/or catecholamines were within reference ranges (non-PHEO). We found that tumour size was significantly larger in PHEO than non-PHEO lesions (44.3 ± 33.2 versus 20.6 ± 9.2 mm respectively; P enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Adrenal Gland NeoplasmsAdultAgedFemaleHumansLipidsMaleMiddle AgedModels, BiologicalPheochromocytomaRetrospective StudiesTomography, X-Ray Computedresearch article35177692open access10.1038/s41598-022-06655-02045-2322PMC8854552https://www.nature.com/articles/s41598-022-06655-0.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854552/pdf